Inhibition of K562 leukemia angiogenesis and growth by expression of antisense vascular endothelial growth factor (VEGF) sequence

Cancer Gene Therapy

Volumn 10, Issue 12, 2003, Pages 879-886

  He, Rui ^a   Liu, Bin ^a   Yang, Chen ^a   Yang, Ren Chi ^a   Tobelem, Gerard ^b   Han, Zhong Chao ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

^b HÔPITAL LARIBOISIÈRE   (France)

Author keywords

Angiogenesis; Antisense VEGF; Gene therapy; Leukemia

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTISENSE VASCULAR ENDOTHELIAL GROWTH FACTOR; COMPLEMENTARY DNA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL MIGRATION; CELL PROLIFERATION; CELL STRAIN K 562; CELL SURVIVAL; CONTROLLED STUDY; CULTURE MEDIUM; DNA SEQUENCE; DRUG MECHANISM; ENDOTHELIUM CELL; ERYTHROLEUKEMIA; FEMALE; GENE THERAPY; HUMAN; HUMAN CELL; LEUKEMIA CELL; MICROVASCULATURE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; UMBILICAL VEIN; VECTOR CONTROL;

CELL LINE, TUMOR; CELL SURVIVAL; DNA, ANTISENSE; DOWN-REGULATION; GENE THERAPY; GENETIC VECTORS; HUMANS; LEUKEMIA, ERYTHROBLASTIC, ACUTE; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

ANIMALIA; MUS MUSCULUS;

EID: 0346122778     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700645     Document Type: Article

References (30)

1. Houck KA, Ferrara N, Winer J, Cachianes G, Li B, Leung DW. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol. 1991;5:1806-1814.
2. Kim KJ, Li B, Armanin M, Gillett N, Phillip HS, Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature. 1993;362:841-844.
3. Toi M, Hosshina, Takayanagi T, Tominaga T. Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer. Jpn J Cancer Res. 1994;85:1045-1049.
4. Drake CJ, Little CD. VEGF and vascular fusion: implication for normal and pathological vessels. J Histochem Cytochem. 1999;47:1351-1356.
5. Weider N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med. 1991;324:1-8.
6. O'Brien T, Cranston D, Fuggle S, Bicknell R, Harris AL. Different angiogenic pathways characterize superficial and invasive bladder cancer. Cancer Res. 1995;55:510-513.
7. Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res. 1995;55:3964-3968.
8. Salven P, Ruotsalainen T, Mattson K, Joensuu H. High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer. Int J Cancer. 1998;79:144-146.
9. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 1989;246:1306-1309.
10. Katoh O, Tauchi H, Kawaishi K, Kimura A, Satow Y. Expression of the vascular endothelial growth factor (VEGF) receptor gene, KDR, in hematopoietic cells and inhibitory effect of VEGF on apoptotic cell death caused by ionizing radiation. Cancer Res. 1995;55:5687-5692.
11. Shalaby F, Ho J, Stanford WL, et al. A requirement for Flk-1 in primitive and definitive hematopoiesis and vasculogenesis. Cell. 1997;89:981-990.
12. Hattori K, Dias S, Heissig B, et al. Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells. J Exp Med. 2001;193:1005-1014.
13. Bellamy WT, Richter L, Frutiger Y, Grogan TM. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res. 1999;59:728-733.
14. Aguayo A, Estey E, Kantarjian H, et al. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood. 1999;94:3717-3721
15. Aguayo A, O'Brien S, Keating M, et al. Clinical relevance of intracellular vascular endothelial growth factor levels in B-cell chronic lymphocytic leukemia. Blood. 2000;96:768-770.
16. Aguayo A, Kantarjian H, Manshouri T, et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood. 2000;96:2240-2245.
17. Brogi E, Schatteman G, Wu T, et al. Hypoxia-induced paracrine regulation of vascular endothelial growth factor receptor expression. J Clin Invest. 1996;97:469-476.
18. Fiedler W, Graeven U, Ergun S, et al. Vascular endothelial growth factor, a possible paracrine factor in human acute myeloid leukemia. Blood. 1997;89:1870-1875.
19. Dias S, Hattori K, Zhou Z, et al. Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J Clin Invest. 2000;106:511-521.
20. List AF. Vascular endothelial growth factor signaling pathway as an emerging target in hematologic malignancies. Oncologist. 2001;6(Suppl 1):24-31.
21. Gerber H-P, Malik AK, Solar GP, et al. VEGF regulates hematopoitic stem cell survival by an internal autocrine loop mechanism. Nature. 2002;417:954-958.
22. Nakashima T, Hudson JM, Clayman GL. Antisense inhibition of vascular endothelial growth factor in human head and neck squamous cell carcinoma. Head Neck. 2000;22:483-488.
23. Mordenti J, Thomsen K, Licko V, Chen H, Meng YG, Ferrara N. Efficacy and concentration-response of murine anti-VEGF monoclonal antibody in tumor-bearing mice and extrapolation to human. Toxicol Pathol. 1999;27:14-21.
24. Lin P, Sankar S, Shan S, et al. Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor. Cell Growth Differ. 1998;9:49-58.
25. Prewett M, Huber J, Yiwen Li, et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res. 1999;59:5209-5218.
26. Dias S, Hattori K, Heissig B, et al. Inhibition of both paracrine and autocrine VEGF/VEGFR2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias. Proc Natl Acad Sci USA. 2001;10857-10862.
27. Kang MA, Kim KY, Seol JY, Kim KC, Nam MJ. The growth inhibition of hepatoma by gene transfer of antisense vascular endothelial growth factor. J Gene Med. 2000;2:289-296.
28. Nguyen JT, Wu P, Clouse ME, Hlatky L, Terwilliger EF. Adeno-associated virus-mediated delivery of antiangiogenic factors as an antitumor strategy. Cancer Res. 1998;58:5673-5677.
29. Fusetti L, Pruneri G, Gobbi A, et al. Human myeloid and lymphoid malignancies in the non-obese diabetic/severe combined immunodeficiency mouse model: frequency of apoptotic cells in vascular endothelial growth factor production. Cancer Res. 2000;60:2527-2534.
30. Dias S, Shmelkov SV, Lam G, Rafii S. VEGF165 promotes survival of leukemic cells by Hsp-90-mediated induction of Bcl-2 expression and apoptosis inhibition. Blood. 2002;99:2532-2540.